Cancer Predisposition | CHOP Research Institute

Cornerstone Blog

Faculty Spotlight: Patient-Centric Research and Care With Aime Franco, PhD

Published on

Jan 27, 2023

Faculty Spotlight:Patient-Centric Research and Care With Aime Franco, PhD

By studying the molecular basis of pediatric thyroid cancer, Dr. Franco seeks to improve outcomes and quality of life for patients.

Cornerstone Blog

Improving Outcomes in Pediatric Oncology: Q&A With Garrett Brodeur, MD

Published on

Jan 3, 2022

Improving Outcomes in Pediatric Oncology

Congratulations to Garrett Brodeur, MD, recipient of the American Society of Pediatric Hematology/Oncology Distinguished Career Award.

Cornerstone Blog

COVID Breathalyzer, Distinguished Career Awardee, Kids’ COVID Vaccine, Youth-Onset Type 2 Diabetes, Mental Health and Greenspace

Published on

Aug 6, 2021

This week’s research news features Dr. Audrey Odom John and her discovery of six breath compounds that could lead to a COVID breathalyzer for kids.

Kalish Laboratory

The Kalish Lab studies the genetic and epigenetic causes of growth disorders and cancer predisposition. The lab focuses on studying Beckwith-Wiedemann syndrome (BWS), the most common epigenetic and cancer predisposition disorder, and also runs the BWS registry and biorepository.

Brodeur Laboratory

Research in the Brodeur Lab focuses on two main areas: nanoparticle drug delivery and cancer predisposition. Nanomedicines allow the delivery of much more drug to the tumor and much less to the patient.

Aime T. Franco, PhD

Dr. Franco researches the molecular basis of the differences between pediatric and adult onset thyroid cancer. She aims to understand how the tumor microenvironment impacts disease progression and response to therapy.

E-mail:

francoa1 [at] chop.edu

Beckwith-Wiedemann Syndrome Program of Excellence

Facilitating interaction between Beckwith-Wiedemann Syndrome (BWS) clinical experts, scientists, patient advocates, and BWS families to improve diagnosis, quality of care, and knowledge about BWS.

Garrett M. Brodeur, MD

Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.

E-mail:

brodeur [at] chop.edu